KRYS Overview

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.

Wall Street analysts forecast KRYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is229.25 USD with a low forecast of 198.00 USD and a high forecast of 278.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Krystal Biotech Inc revenue for the last quarter amounts to 116.36M USD, increased 31.95

Krystal Biotech Inc. EPS for the last quarter amounts to 1.83 USD, increased 52.50

Krystal Biotech Inc (KRYS) has 295 emplpoyees as of May 11 2026.

Today KRYS has the market capitalization of 9.01B USD.